Printer Friendly

VICKI SATO TO HEAD RESEARCH AT VERTEX PHARMACEUTICALS

 VICKI SATO TO HEAD RESEARCH AT VERTEX PHARMACEUTICALS
 CAMBRIDGE, Mass., Aug. 31 /PRNewswire/ -- Vicki Sato, Ph.D., will


join Vertex Pharmaeuticals Incorporated (NASDAQ: VRTX) as vice president, chief scientific officer, and chairman of the Scientific Advisory Board, the company announced today. Dr. Sato, formerly vice president-research at Biogen, Inc., will be assuming the position of chief scientific officer, previously held by Joshua Boger, Ph.D., who was named chief executive officer of Vertex in May 1992.
 "Dr. Sato brings to Vertex over a decade of success in directing drug discovery research," commented Dr. Boger. "Her background in immunology will be of particular importance in the development of our lead compounds for the treatment of autoimmune diseases, transplant rejection, AIDS and HIV infection. She is an important addition to our senior management team."
 Dr. Sato was appointed to the senior research post at Biogen, Inc. in 1988 after joining the company in 1984. As research head at Biogen, she has directed drug candidates in the fields of inflammation, immunology, AIDS therapy and cardiovascular therapy from early research into advanced development.
 Dr. Sato received her doctorate degree in biology from Harvard University and served as associate professor in the Department of Biology at Harvard.
 Vertex is a leader in the use of structure-based rational drug design, a scientific approach to drug discovery which uses atomic level information to design synthetic compounds that interact with protein targets involved in disease processes. Vertex is using advanced techniques of biology, chemistry and biophysics to create novel, small molecule compounds that the company plans to develop as orally deliverable drugs to treat major human diseases. Vertex is concentrating on the development of drugs in the areas of immunology, inflammation and antiviral therapy.
 -0- 8/31/92
 /CONTACT: Stephanie Marrus, director of corporate communications for Vertex, 617-576-3111/
 (VRTX) CO: Vertex Pharmaceuticals Incorporated ST: Massachusetts IN: MTC SU: PER


CH -- NE008 -- 4931 08/31/92 11:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:320
Previous Article:SPRINT NAMES KEVIN BRAUER PRESIDENT OF BUSINESS MARKET GROUP
Next Article:HOUSING SECURITIES INC. MORTGAGE CERTIFICATES 1992-NATIONSBANK-1 RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
HECTOR J. GOMEZ, M.D., PH.D., JOINS VERTEX AS VP MEDICAL AFFAIRS
ROBERT SCHOOLEY, M.D., JOINS VERTEX SCIENTIFIC ADVISORY BOARD
VICKI L. SATO, PH.D., PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND DEVELOPMENT AT VERTEX PHARMACEUTICALS
LYNNE H. BRUM JOINS VERTEX PHARMACEUTICALS AS DIRECTOR OF CORPORATE COMMUNICATIONS
DR. STEPHEN C. HARRISON JOINS VERTEX'S SCIENTIFIC ADVISORY BOARD
DR. EUGENE CORDES JOINS VERTEX'S SCIENTIFIC ADVISORY BOARD
Steven Schmidt Joins Vertex Pharmaceuticals as Director of Information Systems
Vertex Pharmaceuticals Appoints Andrew S. Marks as Patent Counsel
John J. Alam, M.D. Joins Vertex as Vice President, Clinical Development
Vicki L. Sato Promoted to President of Vertex Pharmaceuticals.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters